CTOR
Citius Oncology, Inc. - Common Stock (CTOR)
$50
About Citius Oncology, Inc. - Common Stock (CTOR)
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Details
Daily high
$0.58
Daily low
$0.49
Price at open
$0.55
52 Week High
$1.83
52 Week Low
$0.49
Market cap
50.9M
Dividend yield
-
Volume
145,281
Avg. volume
143,152
P/E ratio
-1.15
Citius Oncology, Inc. - Common Stock News
Details
Daily high
$0.58
Daily low
$0.49
Price at open
$0.55
52 Week High
$1.83
52 Week Low
$0.49
Market cap
50.9M
Dividend yield
-
Volume
145,281
Avg. volume
143,152
P/E ratio
-1.15